Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China

• Jingyang Lin,

  Roles Data curation, Resources, Software, Validation, Writing – original draft

  Affiliation Department of Cardiovascular Medicine, Heart Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China

  ⨯
• Qingxia Fang,

  Roles Data curation, Investigation, Validation

  Affiliation Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China

  ⨯
• Xiaochun Zheng

  Roles Data curation, Software, Writing – original draft

  * E-mail: 13868109173@126.com

  Affiliation Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China

  https://orcid.org/0000-0002-6581-2427

  ⨯